Therapeutic Action of Amphotericin B in Experimental Blastomycosis
Abstract
Amphotericin B is a heptaene isolated from a Streptomyces. It has a marked inhibitory activity on Blastomyces dermatitidis in vitro and a curative activity on experimental blastomycosis in mice and hamsters. In vitro, the growth of the mycelium phase (experiment on four strains of B. dermatitidis) is inhibited during 10 days by 0.1 micrograms/cc (Sabouraud liquid medium). The growth of the yeast phase is inhibited, by 0.7 micrograms/cc (blood-cysteinbrin- heart medium). In vivo, 100% of the mice and hamsters inoculated intraperitoneally with 1,000,000 B. dermatitidis yeasts survive when they receive amphotericin B, orally in dosages from 2 to 8 micrograms per animal. The death-rate of the controls is 100% within 4 weeks. But for a few exceptions, the treated animals do not present any anatomo-pathological lesions and the cultures of spleens, livers and lungs are negative. Amphotericin A and nystatin (both tetraenes), administered orally, are inactive on experimental blastomycosis in mice and hamsters. The effect of subcutaneous injection of amphotericin B is similar to that of ingestion, but provokes a local reaction at the site of injection. Amphotericin B is not toxic at the dosages used in the experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 16, 1967
- Accession Number
- AD0843788
Entities
People
- E. Drouhet
- R. Wilkinson
Organizations
- United States Army Biological Warfare Laboratories